The US Food and Drug Administration (FDA) has revised the authorisations for two monoclonal antibody treatments – bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab and imdevimab).
These treatments are highly unlikely to be active against the Omicron variant, according to the latest data. The FDA is now recommending use of these treatments is limited to only when the patient is likely to have been infected with, or exposed to, a variant that is susceptible to these treatments.
